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2407vasospasm, myocardial bridging, and coronary dissection,
as well as infection such as Kawasaki disease, vasculitis,
and cardiac transplant vasculopathy, may also cause
acute cardiac events during exercise. The present section
makes recommendations on how to evaluate patients
with disease of the coronary arteries and make appro-
priate recommendations for athletic competition. Anom-
alous coronary arteries are considered in the Task Force
4 report (2).
We searched PubMed for English language articles
reporting exercise-related issues related to coronary
diseases. This search produced no clinical trials exam-
ining how competitive athletes with coronary artery
diseases should be advised regarding vigorous exercise
in general or athletic competition in particular. Con-
sequently, the following recommendations are based
on case series, case reports, and consensus among the
committee members.
ATHEROSCLEROTIC CORONARY
ARTERY DISEASE
Patients with ASCAD can be divided into clinically mani-
fest or symptomatic and clinically concealed or asymp-
tomatic subgroups. The former have either experienced
an acute cardiac event or have symptoms consistent with
inducible myocardial ischemia, or they have ﬁndings of
ischemia identiﬁed by a diagnostic testing modality such
as exercise testing with or without adjunctive nuclear or
echocardiographic imaging. This group includes those
with “silent ischemia” who have no symptoms but have
ischemia documented by provocative testing. Patients
with clinically concealed ASCAD are presently and previ-
ously asymptomatic and are diagnosed as having ASCAD
by the presence of coronary artery calciﬁcation on
computerized tomography or by the presence of non-
calciﬁed plaque by coronary computed tomography
angiography but do not have evidence of ischemia on
provocative testing.
Evaluation and recommendations for patients with
ASCAD are based on the following assumptions: 1) The
risk of an acute exertion-related cardiac event is greater in
those who have had a previous acute cardiac syndrome
and lower in those whose ASCAD is clinically silent and
was diagnosed by such techniques as coronary artery
calciﬁcation scanning or computed tomography angiog-
raphy. 2) The risk of an acute exertion-related cardiac
event increases with increasing extent of coronary artery
disease, reduced left ventricular systolic function, the
presence and extent of ischemia, and increased electrical
instability. Unstable or “vulnerable” plaques are often
lipid rich (3), so it is also likely that the risk of an exertion-
related plaque disruption can be reduced by aggressive
lipid-lowering treatment, which has been shown toreduce the lipid content of atherosclerotic plaques (4).
3) Patients with clinically manifest ASCAD should strongly
consider deferring their possible return to athletic
competition to permit lesion regression and regression of
lipid from the plaque. The length of this delay is not
deﬁned, but some have suggested 2 years, because sub-
stantial lesion regression has been documented to occur
within 2 years of aggressive lipid management (5).
Recommendations
1. Athleteswith ASCAD should undergomaximal exercise
testing to evaluate exercise tolerance, the presence of
inducible ischemia, and the presence of exercise-
induced electrical instability. Testing should be per-
formed on the subject’s standard medical regimen,
including b-adrenergic blocking medications (Class I;
Level of Evidence C).
2. Athletes with ASCAD should undergo an evaluation
of left ventricular function (Class I; Level of
Evidence C).
3. Once informed of the results of the evaluations con-
tained in recommendations 1 and 2, adult patients
with ASCAD should participate in the decision as
to whether the health and psychological beneﬁts of
exercise for them outweigh the risk (Class I; Level
of Evidence C).
4. Athletes with ASCAD should undergo aggressive risk
factor reduction with high-intensity statin therapy to
reduce the chance of plaque disruption (6) (Class I;
Level of Evidence A).
5. It is reasonable for athletes with clinically concealed
ASCAD to participate in all competitive activities if
their resting left ventricular ejection fraction is >50%
and they have no inducible ischemia or electrical
instability (Class IIb; Level of Evidence C).
6. It is reasonable for patients with clinically manifest
ASCAD to participate in all competitive activities if
their resting left ventricular ejection fraction is >50%,
they are asymptomatic, and they have no inducible
ischemia or electrical instability (Class IIb; Level of
Evidence C).
7. It is reasonable to restrict patients with clinically
manifest ASCAD that does not fulﬁll the criteria in
recommendation 6 to sports with low dynamic and
low to moderate static demands (Class IIb; Level of
Evidence C).
8. It is reasonable to prohibit patients with clinically
manifest ASCAD from competitive sport participation:
a. For at least 3 months after an AMI or coronary
revascularization procedure (Class IIb; Level of
Evidence C);
b. If they have increasing frequency or worsening
symptoms of myocardial ischemia (Class IIb; Level
of Evidence C).
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2408CORONARY ARTERY SPASM
Focal coronary artery spasm, usually in the presence of
various degrees of coronary atherosclerosis, is a deﬁned
but uncommon cause of life-threatening arrhythmias and
SCD (7,8). It can also be identiﬁed in the absence of
identiﬁable atherosclerotic lesions by provocation studies
(9). Coronary artery spasm in its classic form usually oc-
curs with little or minimally obstructive coronary artery
lesions. Although exercise-induced spasm during stress
testing has been documented, it is uncommon. In most
instances, it was induced during pharmacological stress
tests with either dobutamine or adenosine. Reports of
cardiac arrest survivors in whom coronary artery spasm
has been identiﬁed as the mechanism of cardiac arrest are
limited (10), although the presence of coronary vaso-
motor spasm identiﬁes people with a higher risk of sud-
den death than the general population (11). However,
susceptibility to spasm is not constant over time, being
dependent on the state of the endothelium. Finally,
there are also few data to suggest a speciﬁc propensity
to coronary artery spasm and consequent arrhythmias
in competitive athletes. When coronary vasospasm is
identiﬁed or strongly suspected during exercise, treat-
ment should be initiated with calcium blockers and
nitrates to reduce the possibility of spasm and to con-
trol symptoms.
Recommendations
1. It is reasonable to restrict the small subset with silent
ischemia caused by coronary artery spasm who have
had documented life-threatening arrhythmias and in
whom the absence of clinical pain impedes identiﬁ-
cation of an adequate response to therapy (12) to
sports with low dynamic and low to moderate static
demands (Class IIa; Level of Evidence C).
2. It is reasonable that athletes whose symptoms and
objective evidence of spasm can be controlled with
medications be allowed to participate in all levels of
competition (Class IIb; Level of Evidence C).SPONTANEOUS CORONARY ARTERY DISSECTION
Spontaneous coronary artery dissection refers to dissec-
tion of the coronary arteries without underlying athero-
sclerosis (13). Spontaneous coronary artery dissection is
associated with late pregnancy and the peripartum state,
female hormonal therapy, Marfan syndrome, exercise,
chest trauma (13), and ﬁbromuscular dysplasia (14). It is a
rare cause of exercise-related cardiac events but should
be considered in any young person who develops an
acute cardiac syndrome during vigorous exercise or after
sports-related chest trauma.Recommendation
1. There are insufﬁcient data to provide deﬁnitive rec-
ommendations for sports participation, but because
spontaneous dissection can occur with exertion, it is
reasonable that patients with prior spontaneous coro-
nary artery dissection be restricted to participation in
sports with low to moderate dynamic and low to mod-
erate static demands (Class IIa; Level of Evidence C).MYOCARDIAL BRIDGING
Myocardial bridging is diagnosed when a portion of a
major epicardial coronary artery is completely covered by
myocardium. Myocardial bridging is commonly observed
by angiography as coronary artery compression during
systole. It is usually asymptomatic and of no clinical
consequence but has been rarely associated with exercise-
induced ischemia and exercise-related acute cardiac
events (15). Pathological studies suggest that vessels
whose tunneled length is long and deeper than 3 mm
beneath the epicardium create the greatest vulnerability
for cardiac events.
Recommendations
1. It is reasonable for athletes with myocardial bridging
and no evidence of myocardial ischemia during
adequate stress testing to participate in all competi-
tive sports (Class IIa; Level of Evidence C).
2. It is reasonable to restrict athletes with myocardial
bridging of an epicardial coronary artery and objective
evidence of myocardial ischemia or prior myocardial
infarction to sports with low to moderate dynamic and
low to moderate static demands (Class IIa; Level of
Evidence C).
3. It is reasonable to restrict athletes who have undergone
surgical resection of the myocardial bridge or stenting
of the bridge to low-intensity sports for 6 months after
the procedure. If such athletes have no subsequent
evidence of ischemia, they may participate in all
competitive sports (Class IIa; Level of Evidence C).KAWASAKI DISEASE
Kawasaki disease is an acute febrile illness of unknown
pathogenesis that is among the leading causes of acquired
heart disease in children. Kawasaki disease can produce
coronary artery aneurysms that predispose to myocardial
ischemia, myocardial infarction, and SCD. Aneurysms can
be divided by their internal diameter into small (<1.5
times normal, or <5 mm), moderate (1.5 to 4 times normal,
or 5 to 8 mm), and large (>4 times normal, or >8 mm)
aneurysms (16). Prompt recognition and treatment of the
acute phase of Kawasaki disease can reduce the cardiac
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2409complications, but 20% of untreated people and 4% of
those treated with aspirin and intravenous immunoglob-
ulin still develop coronary artery aneurysms (17). Risk
scores for prediction of coronary artery aneurysm devel-
opment are imperfect, and the broad use of intravenous
immunoglobulin is recommended. Ongoing surveillance
of patients after the acute phase is recommended,
including serial stress tests in those patients with mani-
fest coronary artery disease (18). Treatment of coronary
artery aneurysms with antiplatelet agents, anticoagulant
agents, or myocardial revascularization must be consid-
ered in evaluating decisions about a patient’s return to
competition.
Recommendations
1. Patients with ‡1 large coronary aneurysms should
continue antiplatelet therapy and possibly anticoag-
ulant therapy. It is also reasonable for annual stress
tests to be performed and activity to be guided by
results, similar to adults with ASCAD (Class I; Level of
Evidence C).
2. Patients with myocardial infarction or revasculariza-
tion should follow the guidance for adults with ASCAD
(Class I; Level of Evidence A).
3. Collision sports should be avoided in patients
undergoing antiplatelet therapy (Class I; Level of
Evidence C).
4. In the absence of exercise-induced ischemia or ar-
rhythmias, it is reasonable for patients to participate
in low- to moderate-intensity static and dynamic
competitive sports. Patients with persistent small to
medium-sized aneurysms in ‡1 coronary arteries
should continue antiplatelet therapy and undergo
ongoing surveillance (Class IIa; Level of Evidence C).
5. Patients with no coronary aneurysms during the
convalescent phase and with no exercise-induced
ischemia or arrhythmias may be considered for
participation in all sports starting 8 weeks after the
illness has resolved (Class IIb; Level of Evidence C).
6. Patients with transient coronary aneurysms and with
no exercise-induced ischemia or arrhythmias may be
considered for participation in all sports 8 weeks after
illness resolution. Risk reassessment is recommended
at 3- to 5-year intervals or according to current
guidelines (Class IIb; Level of Evidence C).
CORONARY VASCULITIS
Coronary vasculitis attributable to causes other than Ka-
wasaki disease may affect competitive athletes of any age
but is rare. These diseases include polyarteritis nodosa,
Takayasu arteritis, Buerger disease, and other speciﬁc and
nonspeciﬁc forms of coronary arteritis (16). SCD has been
reported in previously healthy young people withunsuspected coronary vasculitis at autopsy (17). In a
series of 50 cases of SCD associated with nonathero-
sclerotic coronary pathology (12 of whom died during or
immediately after physical exertion), 6 of the 50 (12%) had
autopsy evidence of coronary vasculitis (18).
There is no evidence that athletes are predisposed to
coronary vasculitis at rates higher than the general age-
corrected population or that the course of these ath-
letes’ disease is any different from that of the general
population. There is no information in the medical liter-
ature to suggest care of the athlete should differ.
Recommendations
1. Athletes who have recovered from coronary vascu-
litis can participate in all sports without restriction
(Class I; Level of Evidence C).
2. Athletes with coronary vasculitis are likely at
increased risk for acute cardiac events during training
or competition. It is reasonable to restrict participa-
tion in sports until the vasculitis has resolved
(Class IIa; Level of Evidence C).CARDIAC TRANSPLANT CORONARY
VASCULOPATHY
The coronary arteries of orthotopic transplanted hearts
develop a diffuse vasculopathy that is the leading cause of
death in transplant recipients. Because the transplanted
heart is initially denervated, recipients require surveil-
lance, because they may not experience classic symptoms
of cardiac ischemia. Our literature search did not detect
any reports of exercise-related cardiac events in cardiac
transplant recipients either because transplant vasculop-
athy is not associated with the same increase in exercise
events as classic atherosclerosis or because too few
transplant patients have participated in competitive
events to highlight this issue.
Recommendations
1. The transplant cardiologist should make the ﬁnal
recommendations for athletic participation for cardiac
transplant recipients (Class I; Level of Evidence C).
2. It is reasonable for cardiac transplant recipients
participating in competitive athletics to undergo
yearly maximal exercise testing with echocardiogra-
phy using a protocol designed to simulate the cardiac
and metabolic demands of the competitive event and
its training regimen (Class IIa; Level of Evidence C).
3. It is reasonable for cardiac transplant recipients
with an ejection fraction >50%, no evidence of cardiac
ischemia, and no electrical instability to participate in
all competitive activities commensurate with their
exercise tolerance (Class IIa; Level of Evidence C).
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